Author

S. Napoli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Assay:DNA methylation· 1

Frequent Co-Authors

A. J. Arribas· 4 shared F. Bertoni· 4 shared L. Cascione· 4 shared A. Rinaldi· 3 shared D. Rossi· 3 shared F. Spriano· 3 shared A. Cavalli· 2 shared A. Stathis· 2 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. J. Arribas

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

F. Spriano, L. Cascione, J. Sgrignani, N. Bendik, S. Napoli, G. Sartori, E. Cannas, T. Gong, A. J. Arribas, M. Pizzi, D. Rossi, D. F. Robbiani, A. Cavalli, F. Bertoni

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

bioRxiv · Jan 17, 2024 · PreprintCancer Biology

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

A. J. Arribas, E. Gaudio, S. Napoli, C. J. Herbaux, C. Tarantelli, R. Bordone Pittau, L. Cascione, N. Munz, L. Aresu, J. Sgrignani, A. Rinaldi, I. Kwee, D. Rossi, A. Cavalli, E. Zucca, , F. Bertoni

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

bioRxiv · Nov 14, 2023 · PreprintCancer Biology

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

A. J. Arribas, S. Napoli, L. Cascione, L. Barnabei, G. Sartori, E. Cannas, E. Gaudio, C. Tarantelli, A. A. Mensah, F. Spriano, A. Zucchetto, F. M. Rossi, A. Rinaldi, M. Castro de Moura, S. Jovic, , F. Bertoni

This study identifies ERBB4-mediated signaling as a mechanism of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms and shows that targeting ERBB signaling can restore sensitivity.

bioRxiv · Jan 1, 2023Cancer Biology

Assessment of lisavanbulin (BAL101553) as an anti-lymphoma agent

F. Spriano, L. Aresu, L. Cascione, G. Risi, A. J. Arribas, S. Napoli, A. Rinaldi, N. Forster-Gross, F. Bachmann, M. Engelhardt, H. Lane, F. Bertoni

This study evaluates lisavanbulin's anti-lymphoma activity and EB1 expression in DLBCL, showing potent in vitro cytotoxicity and potential clinical relevance.

bioRxiv · Dec 31, 2022 · PreprintCancer Biology